Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nipro's Enterprise Value is 円857,077 Mil.
Nipro's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円39,251 Mil. Therefore, Nipro's EV-to-EBIT ratio for today is 21.84.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Nipro's Enterprise Value is 円857,077 Mil.
Nipro's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円102,988 Mil. Therefore, Nipro's EV-to-EBITDA ratio for today is 8.32.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Nipro's Enterprise Value is 円857,077 Mil.
Nipro's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円660,538 Mil. Therefore, Nipro's EV-to-Revenue ratio for today is 1.30.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Nipro's Enterprise Value is 円857,077 Mil.
Nipro's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil. Therefore, Nipro's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Nipro (TSE:8086) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Nipro's current Enterprise Value is 円857,077 Mil.
Nipro's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円39,251 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Nipro's current Enterprise Value is 円857,077 Mil.
Nipro's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円102,988 Mil.
Nipro's current Enterprise Value is 円857,077 Mil.
Nipro's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円660,538 Mil.
Nipro's current Enterprise Value is 円857,077 Mil.
Nipro's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
Nipro's current Enterprise Value is 円857,077 Mil.
Nipro's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro Enterprise Value Related Terms
Nipro Enterprise Value Historical Data
* Premium members only.
The historical data trend for Nipro's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:8086 vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Nipro's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Nipro's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Nipro's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of 円857,077 Mil mean?
Nipro (TSE:8086) has a Enterprise Value of 円857,077 Mil as of Jul. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Nipro and its competitors.
Is Nipro's Enterprise Value too high?
Nipro's current Enterprise Value is 円857,077 Mil. Overall, Nipro has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nipro's Enterprise Value compare to ISRG and BDX?
Nipro's Enterprise Value of 円857,077 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Nipro and its competitors. Nipro's current Enterprise Value is 円857,077 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Based on GuruFocus' analysis, Nipro (TSE:8086) is currently considered Fairly Valued. The stock's GF Value™ is 円1,457.04, compared to a current price of 円1,552.50 — trading 6.6% above its estimated fair value. The current Enterprise Value is 円857,077 Mil. Nipro's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Nipro (TSE:8086), the current Enterprise Value is 円857,077 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (TSE:8086) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of 円1,552.50 is trading 6.6% above its estimated GF Value™ of 円1,457.04.
GuruFocus considers Nipro to be Fairly Valued.
Key valuation signals for TSE:8086:
Enterprise Value: 円857,077 Mil
GF Value™: 円1,457.04 vs. price of 円1,552.50 (6.6% above fair value)
No single metric tells the full story. See the TSE:8086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
70GF Score
Get the complete analysis for TSE:8086
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:8086 has been successfully added to your 
